CORRECTING and REPLACING -- Trxade Group Achieves Record

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTING and REPLACING -- Trxade Group Achieves Record First Quarter 2016 Financial Results Driven by a 165% Increase in Revenues Over First Quarter 2015

TAMPA, Fla., April 21, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Trxade Group, Inc. (OTCQB: TRXD) we are advised by the company that the third bullet point under "First Quarter Highlights" should read "Net loss narrowed to ($372,380)" rather than "Operating loss narrowed to ($372,380)" as previously stated.

The corrected release follows:

First Quarter Highlights:

  • Company achieves record revenues of $1.8 million in quarter ending March 31, 2016, an increase of 165% over $696,000 in quarter ending March 31, 2015
  • Gross profit increased to $831,069 from $465,670 in quarters ending March 31, 2016 and 2015, respectively
  • Net loss narrowed to ($372,380) from ($443,620) in the quarter ending March 31, 2016 and 2015, respectively
  • Trxade’s trading platform achieves record quarterly operating profit for 1Q16
  • As of end of 1Q16, Trxade has added over 441 independent pharmacies to its trading platform, to reach a record 5,500 members
  • Company launches HCTZ (Hydrochlorothiazide) to treat fluid edema in 1Q16

Trxade Group, Inc. (OTCQB: TRXD), a pharmaceutical company that distributes private label pharmaceuticals through its wholly-owned subsidiary Westminster Pharmaceuticals, LLC and Trxade, Inc. a web-based market platform that enables registered independent pharmacies to quickly source and purchase pharmaceuticals, accessories and services from a wide range of manufacturers and drug distributors, today reported financial results for its first quarter, ended March 31, 2016 and provided a business update and positive outlook for 2016.

Company Produces 165% Increase in First Quarter Revenues, a New Record

Revenues for the three months ended March 31, 2016 were $1,847,151 -- an increase of 165% over $696,133 in the year-ago quarter, and 24% higher sequentially over the fourth quarter ended December 31, 2015.  The revenue growth was primarily attributable to increased wholesale pharmaceutical sales from its wholly owned subsidiary Westminster Pharmaceuticals, LLC and an increase of fee income generated from the Company’s web-based supplier-to-pharmacy trading platform ( www.trxade.com ).

For the first quarter ended March 31, 2016, the Company reported that its net loss narrowed to ($372,380), or ($0.01) per basic and diluted share, compared with a net loss of ($443,620), or ($0.01) per basic and diluted share in the year ago quarter and versus ($495,445), or ($0.02) per basic and diluted share, for the fourth quarter of 2015. 

The Company’s cost of sales was $1,016,082 and $230,463 for the quarters ending March 31, 2016 and 2015, respectively. This increase reflected a sales mix with greater revenue from wholesale pharmaceutical sales, which carries a higher cost of sales than the Company’s other revenue sources. Gross profit increased to $831,069 from $465,670 in the quarter ending March 31, 2016 and 2015, respectively.

While general and administrative expenses increased to $1,140,816 in the first quarter of 2016 compared with $908,321 in the year-ago quarter, it decreased sequentially from $1,317,412 in the fourth quarter of 2015.  Operating losses for the first quarter of 2016 narrowed to ($309,747) versus ($442,651) in the year-ago quarter, and narrowed sequentially from ($441,385) from the fourth quarter, ended December 31, 2015. 

Company Launches HCTZ (Hydrochlorothiazide) to Treat Fluid Edema in First Quarter of 2016

During the first quarter of 2016, the Company also announced that its wholly-owned subsidiary, Westminster Pharmaceuticals LLC, has launched the generic drug HCTZ (Hydrochlorothiazide) as part of an agreement with ScieGen Pharmaceuticals, Inc.  ScieGen’s ANDA Number 203018 for Hydrochlorothiazide treats fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen. This medication, which is also used to treat high blood pressure (hypertension), will be marketed under the Westminster Pharmaceuticals, LLC private label.  Under the terms of the supply and distribution agreement with ScieGen, Westminster will semi-exclusively market and distribute ScieGen’s product in the United States.

CEO Sees Continuing Strong Revenue Growth and Profitability in 2016

“Our proprietary trading platform at www.trxade.com , which enables independent pharmacies to purchase drugs at an average discount of between 15%-20%, is adding new members on a monthly basis at record levels and, as a result, enabling us to experience strong top and bottom line growth across the board,” said Suren Ajjarapu, Chairman and Chief Executive Officer of Trxade Group. “Our 2016 fiscal year is off to a record start -- well ahead of our internal plan and budget -- and in-line with our primary objective of expanding our membership base while simultaneously focusing on increasing their utilization rates.  At the end of the first quarter, we reported record platform subscribers, record transactional revenue, record gross profit – along with net and operating losses both narrowing substantially in the first quarter of 2016.

“Accordingly, I am optimistic we will reach profitability in the current fiscal year as increasing pharmaceutical prices drive independent pharmacies and payors and consumers to be more aggressive in sourcing medication. In response to increasing customer demand, we are actively developing new product offerings and increased data analytics capability to add greater value by helping the independent pharmacies better manage their inventory and costs,” Mr. Ajjarapu concluded.

About Trxade Group, Inc.             Headquartered in Tampa, Florida, Trxade Group, Inc. (OTCQB: TRXD) is a pharmaceutical company that distributes private label pharmaceuticals wholesale through its wholly-owned subsidiary Westminster Pharmaceuticals, LLC and Trxade, Inc., with over 5,500 registered independent pharmacies, is a web-based market platform that enables the pharmacies to quickly source and purchase pharmaceuticals, accessories and services from a wide range of manufacturers and drug distributors. For additional information, please visit us at www.trxadegroup.com . 

Forward-Looking Statements             The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. Except as may be required by applicable law, we assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  The company undertakes no duty to update forward-looking statements.

Trxade Group, Inc.
Consolidated Balance Sheets
(unaudited)
   
     
  March 31, 2016 December 31, 2015
Assets    
     
Current Assets    
Cash   $ 508,279       $ 860,132    
Accounts Receivable, net     452,141         498,100    
Inventory, net     475,862         284,718    
Prepaid Assets     220,095         201,361    
Other Assets      167,509         183,359    
Total Current Assets     1,823,886         2,027,670    
     
Total Assets   $ 1,823,886       $ 2,027,670    
     
Liabilities and Shareholders’ Equity (Deficit)  
Current Liabilities    
Accounts Payable   $ 338,541       $ 356,159    
Accrued Liabilities     396,477         296,803    
     
Notes Payable net of $3,750 and $15,000 discount     246,250         235,000    
Short term Convertible Payable    
  net of $8,923 and $35,697 discount     191,077         164,303    
Total Current Liabilities     1,172,345         1,052,265    
     
Long Term Liabilities    
Convertible Note net of $220,621 and     
$241,612 discount     729,379         708,388    
Total Liabilities     1,901,724         1,760,653    
     
Shareholders’ Equity/Deficit    
Preferred Stock, $0.00001 par value; 10,000,000    
shares authorized; 0 shares issued and outstanding,    
 as of March 31, 2016 and December 31, 2015,     
 respectively     --         --    
     
Common Stock, $0.00001 par value; 100,000,000    
shares authorized; 31,435,827 and 31,435,827    
shares issued and outstanding, as of March 31, 2016     
and December 31, 2015, respectively     314         314    
     
Additional Paid-in Capital     5,943,199         5,915,674    
Retained Earnings (Deficit)     (6,021,351 )        (5,648,971 )   
Total Shareholders’ Equity (Deficit)     (77,838 )        267,017    
     
Total Liabilities and Shareholders’ Equity (Deficit)   $ 1,823,886       $ 2,027,670    

 

Trxade Group, Inc.  
Consolidated Statements of Operations  
(unaudited)  
     
  Three Months Ended March 31,  
      2016         2015      
       
Revenues   $ 1,847,151       $ 696,133      
       
Cost of Sales     1,016,082         230,463      
Gross Profit     831,069         465,670      
       
Operating Expenses      
General and Administrative     1,140,816         908,321      
       
Operating Loss     (309,747 )        (442,651 )     
       
Interest Expense     62,633         969      
       
Net Loss   $ (372,380 )      $ (443,620 )     
       
Basic loss per Common Share   $  (.01 )     $  (.01 )    
       
Diluted loss per Common Share   $  (.01 )     $  (.01 )    
       
Basic weighted average number of       
Common Shares outstanding     31,435,827         31,269,160      
       
Diluted weighted average number of       
Common Shares outstanding     31,435,827         31,269,160      
   

 

 

Investor and Media Contacts:                        Todd Markey Vice President, Investor Relations tmarkey@irpartnersinc.com Phone: 818-280-6801

Scroll down for more posts ▼

Top 10 Most Recent News Articles

1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 73

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 167

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 60

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 98

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 112

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 7

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 5

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading

Top 5 Most Recently Viewed Articles

City Office REIT's 2024 Q3 Performance and Strategic Outlook

Updated Category News Views 266

City Office REIT's Third Quarter 2024 Financial Results Overview City Office REIT, Inc. (NYSE: CIO) has recently released its financial results for the third quarter of 2024. In this quarter's report, the company highlighted a substantial progression in its office real estate fundamentals, showcasing resilience and strategic maneuvers in a competitive market. Key...

Continue Reading
Latest Transactions of Ringkjøbing Landbobank A/S Shares

Updated Category News Views 146

Overview of Share Transactions In the realm of financial regulations, the duty of disclosure plays a crucial role. When it comes to transactions involving shares, companies must adhere to specific guidelines to maintain transparency. Recently, Ringkjøbing Landbobank A/S has reported its share transactions, which is particularly important for stakeholders, regulatory...

Continue Reading
Unlocking Success: The Power of Trust in Business Practices

Updated Category News Views 280

Trust as the Foundation of Business Success Recent insights have emerged showing that trust not only fosters a positive workplace culture but also serves as a significant catalyst for long-term financial prosperity. According to research from Great Place To Work®, companies that prioritize trust within their employee relationships consistently outperform their...

Continue Reading
Investing in Texas Instruments: A 15-Year Journey of Growth

Updated Category News Views 126

The Impressive Growth of Texas Instruments Texas Instruments (NASDAQ: TXN), a leader in semiconductor technology, has demonstrated remarkable performance over the last 15 years. With an annualized return of 15.69%, it has surpassed market averages by 3.27%. This kind of consistent growth illustrates why many investors find TXN appealing. Your $1000 Investment in TXN If an...

Continue Reading
Sarah Schmelzel Joins SERVPRO as New Brand Ambassador

Updated Category News Views 414

Sarah Schmelzel Becomes a SERVPRO Brand Ambassador Gallatin, Tennessee – SERVPRO, a well-regarded leader in cleanup, restoration, and construction, proudly announces the partnership with LPGA golfer Sarah Schmelzel as a brand ambassador for the upcoming season. This collaboration underscores SERVPRO’s deep-rooted involvement with top-tier sports organizations,...

Continue Reading